Providers on the topic

The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions. (Source: Pixabay)
Business Strategy

Ashland to Sell its Nutraceuticals Business

Ashland has entered into a definitive agreement with Turnspire Capital Partners to sell its nutraceuticals business. The business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well as custom formulation and contract manufacturing capabilities for the nutrition market.

Read on

Galleries